KFDA approves Micardis for hypertension

Published: 2010-01-28 06:58:00

Updated: 2010-01-28 06:58:00

The Korea Food and Drug Administration said on January 22 that it has approved the supplemental indication of Micardis (telmisartan), an angiotensin II receptor blocker (ARB), for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of a...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK